<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563678</url>
  </required_header>
  <id_info>
    <org_study_id>1040229</org_study_id>
    <nct_id>NCT02563678</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines</brief_title>
  <acronym>O2B</acronym>
  <official_title>Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this small pilot study, participants (patients and healthy volunteers) will have blood&#xD;
      drawn before and after the study intervention (hyperbaric chamber session or normal pressure&#xD;
      oxygen breathing. This blood will be analyzed for neutrophil oxidative burst and cytokine&#xD;
      analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are interested in studying the influence of hyperbaric oxygen on&#xD;
      neutrophils (a kind of white blood cell) and cytokines (cell proteins). Hyperbaric oxygen can&#xD;
      enhance the way the immune system works, but the investigators don't fully know how that&#xD;
      happens. the investigators are doing this study to learn more about this question.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative Burst Assay</measure>
    <time_frame>Within 30 minutes after chamber session 1</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Diabetics with active, chronic infection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No diabetes or infection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Critically ill patients with infection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbon monoxide patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose tolerance test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brain injury research subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric chamber inside attendants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volunteers, hyperbaric oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volunteers, normobaric pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric Oxygen</intervention_name>
    <description>Hyperbaric oxygen therapy</description>
    <arm_group_label>Brain injury research subjects</arm_group_label>
    <arm_group_label>Carbon monoxide patients</arm_group_label>
    <arm_group_label>Critically ill patients with infection</arm_group_label>
    <arm_group_label>Diabetics with active, chronic infection</arm_group_label>
    <arm_group_label>Glucose tolerance test</arm_group_label>
    <arm_group_label>No diabetes or infection</arm_group_label>
    <arm_group_label>Volunteers, hyperbaric oxygen</arm_group_label>
    <other_name>HBO, HBO2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperbaric Air/Oxygen</intervention_name>
    <description>Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber</description>
    <arm_group_label>Hyperbaric chamber inside attendants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normobaric oxygen</intervention_name>
    <description>Breathing 100% oxygen at normal, atmospheric pressure</description>
    <arm_group_label>Volunteers, normobaric pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Cohort 1: Diabetic hyperbaric patients with active, chronic infection&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (ages 18-65) presenting for an anticipated course of at least 4&#xD;
             hyperbaric oxygen sessions for chronic clinical indications (possible indications&#xD;
             include diabetic lower extremity wounds or refractory osteomyelitis)&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Current antibiotic use for active infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with hyperbaric oxygen within the last 30 days&#xD;
&#xD;
          -  Consistent vitamin C or vitamin E supplementation in the past year&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Cohort 2: Hyperbaric patients without diabetes or active infection&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - Adult patients (ages 18-65) presenting for an anticipated course of at least 4 hyperbaric&#xD;
        oxygen sessions for chronic clinical indications (possible indications include crush&#xD;
        injury, acute peripheral arterial insufficiency, or radiation necrosis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with hyperbaric oxygen within the last 30 days&#xD;
&#xD;
          -  Consistent vitamin C or vitamin E supplementation in the past year&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Known or suspected viral or bacterial infection&#xD;
&#xD;
        Cohort 3: Critically ill hyperbaric patients with acute infection&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - Adult patients (ages 18-65) admitted to the intensive care unit for acute,&#xD;
        life-threatening infection where hyperbaric oxygen is clinically indicated for at least 4&#xD;
        sessions (possible indications include gas gangrene or necrotizing fasciitis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with hyperbaric oxygen within the last 30 days&#xD;
&#xD;
          -  Consistent vitamin C or vitamin E supplementation in the past year&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Cohort 4:&#xD;
&#xD;
        Carbon monoxide-poisoned patients&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - Adult patients (ages 18-65) presenting for hyperbaric oxygen for acute carbon monoxide&#xD;
        poisoning (up to 3 sessions)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with hyperbaric oxygen within the last 30 days&#xD;
&#xD;
          -  Consistent vitamin C or vitamin E supplementation in the past year&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Time interval between removal from carbon monoxide source and first hyperbaric oxygen&#xD;
             session &gt;12 hours&#xD;
&#xD;
        Cohort 5: Diabetic research subjects also undergoing glucose tolerance testing&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Co-enrollment in glucose tolerance testing study&#xD;
&#xD;
          -  Meet inclusion/exclusion profile for that study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with hyperbaric oxygen within the last 30 days&#xD;
&#xD;
          -  Consistent vitamin C or vitamin E supplementation in the past year&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
        Cohort 6: Brain injury research subjects&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Co-enrollment in brain injury study&#xD;
&#xD;
          -  Meet inclusion/exclusion profile for that study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected viral or bacterial infection&#xD;
&#xD;
          -  Consistent vitamin C or vitamin E supplementation in the past year&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
        Cohort 7: Hyperbaric chamber inside attendants&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - Employees (ages 18-65) medically cleared to work as hyperbaric chamber inside attendants,&#xD;
        reporting for a regular duty day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected viral or bacterial infection&#xD;
&#xD;
          -  Consistent vitamin C or vitamin E supplementation in the past year&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
          -  Prior work in the hyperbaric chamber in the last 72 hours&#xD;
&#xD;
        Cohort 8: Healthy volunteers to receive hyperbaric oxygen&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers (ages 18-65)&#xD;
&#xD;
          -  Medical clearance for hyperbaric oxygen exposure&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Hyperbaric oxygen exposure within the last 30 days&#xD;
&#xD;
          -  Active chronic medical condition&#xD;
&#xD;
          -  Use in the past 30 days of any over-the-counter or prescription medication or dietary&#xD;
             supplement beyond a general multivitamin&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
          -  History of significant health problems, including metabolic bone disease, skeletal&#xD;
             muscle pathologies, cardiac or peripheral cardiovascular system abnormalities,&#xD;
             clotting disorders, coronary artery disease, peripheral vascular disease, stroke,&#xD;
             cancer, high cholesterol or triglycerides, high blood pressure, diabetes mellitus, or&#xD;
             impaired liver/kidney function.&#xD;
&#xD;
          -  Morbidly obese (body mass index &gt; 40 kg/m2)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known or suspected viral or bacterial infection&#xD;
&#xD;
        Cohort 9: Healthy volunteers to breathe 100% oxygen at atmospheric pressure&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - Healthy volunteers (ages 18-65)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Hyperbaric oxygen exposure within the last 30 days&#xD;
&#xD;
          -  Active chronic medical condition&#xD;
&#xD;
          -  Use in the past 30 days of any over-the-counter or prescription medication or dietary&#xD;
             supplement beyond a general multivitamin&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
          -  History of significant health problems, including metabolic bone disease, skeletal&#xD;
             muscle pathologies, cardiac or peripheral cardiovascular system abnormalities,&#xD;
             clotting disorders, coronary artery disease, peripheral vascular disease, stroke,&#xD;
             cancer, high cholesterol or triglycerides, high blood pressure, diabetes mellitus, or&#xD;
             impaired liver/kidney function.&#xD;
&#xD;
          -  Morbidly obese (body mass index &gt; 40 kg/m2)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known or suspected viral or bacterial infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindell K Weaver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Health Care, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindell K Weaver, MD</last_name>
    <phone>801-408-3623</phone>
    <email>lindell.weaver@imail.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Churchill, APRN-NP</last_name>
    <phone>801-408-3623</phone>
    <email>susan.churchill@imail.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Churchill, APRN-NP</last_name>
      <phone>801-408-3623</phone>
      <email>susan.churchill@imail.org</email>
    </contact>
    <investigator>
      <last_name>Lindell K. Weaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare, LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Churchill, APRN-NP</last_name>
      <phone>810-408-3623</phone>
      <email>Susan.Churchill@imail.org</email>
    </contact>
    <investigator>
      <last_name>Lindell K Weaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Churchill, APRN-NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Intermountain Health Care, Inc.</investigator_affiliation>
    <investigator_full_name>Lindell Weaver</investigator_full_name>
    <investigator_title>Director, Hyperbaric Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

